Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 27.0 Cr.
- Current Price ₹ 23.0
- High / Low ₹ 49.7 / 19.6
- Stock P/E 5.89
- Book Value ₹ 27.9
- Dividend Yield 0.00 %
- ROCE 16.9 %
- ROE 17.8 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.83 times its book value
- Promoter holding has increased by 1.54% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Company has high debtors of 247 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 25.27 | 38.19 | 39.43 | |
| 20.53 | 31.58 | 32.16 | |
| Operating Profit | 4.74 | 6.61 | 7.27 |
| OPM % | 18.76% | 17.31% | 18.44% |
| 1.07 | 0.10 | 0.11 | |
| Interest | 0.65 | 0.54 | 0.62 |
| Depreciation | 0.72 | 0.74 | 0.78 |
| Profit before tax | 4.44 | 5.43 | 5.98 |
| Tax % | 40.77% | 25.41% | |
| 2.62 | 4.05 | 4.58 | |
| EPS in Rs | 3.05 | 3.46 | 3.91 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 8.60 | 11.70 | 11.70 |
| Reserves | 6.66 | 18.43 | 20.92 |
| 12.66 | 12.35 | 15.67 | |
| 10.52 | 16.73 | 12.86 | |
| Total Liabilities | 38.44 | 59.21 | 61.15 |
| 10.35 | 10.13 | 12.79 | |
| CWIP | 0.15 | 2.22 | 0.36 |
| Investments | 0.00 | 0.00 | 0.00 |
| 27.94 | 46.86 | 48.00 | |
| Total Assets | 38.44 | 59.21 | 61.15 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.66 | -4.54 | |
| -0.34 | -2.35 | |
| 4.01 | 10.47 | |
| Net Cash Flow | 0.01 | 3.58 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 241.21 | 247.06 |
| Inventory Days | 244.39 | 228.39 |
| Days Payable | 281.81 | 356.77 |
| Cash Conversion Cycle | 203.80 | 118.69 |
| Working Capital Days | 74.24 | 135.14 |
| ROCE % | 16.88% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Tablets Sales Contribution % ・Includes some standalone data |
|
|||
| Installed Capacity - Capsules Lakh capsules per annum ・Standalone data |
||||
| Installed Capacity - Dry Powder Sachets Units per annum ・Standalone data |
||||
| Installed Capacity - Ointment Kg per annum ・Standalone data |
||||
| Installed Capacity - Suspension/Oral Liquids Liters per annum ・Standalone data |
||||
| Installed Capacity - Tablets Lakh tablets per annum ・Standalone data |
||||
| Geographic Presence (Countries) Number |
||||
| Capacity Utilization (Average) % ・Standalone data |
||||
| Order Book - Povidone Iodine Solution Units ・Standalone data |
||||
| Total Product SKUs Number |
||||
Documents
Announcements
-
General Updates
18 March 2026 - EGM notice dispatched; ads published in Financial Express and Jansatta on March 18, 2026.
-
Shareholders meeting
17 March 2026 - EGM Apr 9,2026: increase authorised capital by Rs6Cr; preferential issue Rs7Cr; warrants Rs4.15Cr; loan conversion Rs2.5Cr.
-
Outcome of Board Meeting
13 March 2026 - Propose authorised capital increase to Rs20 crore; preferential issue up to 20L shares and 11,85,715 warrants at Rs35 each.
-
Shareholders meeting
27 February 2026 - Postal ballot approved Feb 27, 2026: IPO objects variation; remuneration excess; reappointment of Ashutosh Gupta.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
28 January 2026 - Reconciliation of Share Capital Audit for quarter ended Dec 31, 2025; issued capital 11,700,000 shares.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPTREC
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.